{"name":"Immunitas Therapeutics","slug":"immunitas-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNUGdZM09YM19EUjhHaElKb1VDYWVUYlBsWFpSMWxYMEtlVF8zMEVZYjc1LUx6cWp1MWRIMmhSc1VuTkVLY1R3M2hqUWM5TlJYUHdob053WUZ5RWYwYjhjZVlqSGRFdFVJMHl1YllzTW1SOXlxNXJLT3lUNnNBbG9LSWpBTHZ6VzhETmVkRzdOcG1GQWR2Y0dBazBVZE5ZaTJfVGVr?oc=5","date":"2025-07-31","type":"pipeline","source":"BioWorld News","summary":"Immunitas Therapeutics unveils anti-CD161 antibody candidate - BioWorld News","headline":"Immunitas Therapeutics unveils anti-CD161 antibody candidate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxQTVhBaDFqUHNqZ1FOX1dMUFc4YnVoWlNWaVlkeXlrR3dQLW41NjBTeUxKT1JwMVFPVWNVQllpLWJ3U2VxN0lNWEtSXy1BbGh2c0VhVmY2eVNxdXJmaFY5X091R0VSRm9KVDlKWkwwTlBEVWdmV294Y1R3MzVjTzUzX3c4aDZDbDdCaXBPX3A0WHoyZ1ZCSW9JM1ptVEwxdzYzeWFhX0k3czZYR2ZsZ2lIM0JIT0RHQml0V2J4VmpkdkFkV0kwanJFemo4QlpNUQ?oc=5","date":"2025-07-15","type":"pipeline","source":"Healio","summary":"Researchers identify most effective, safest therapeutics for hidradenitis suppurativa - Healio","headline":"Researchers identify most effective, safest therapeutics for hidradenitis suppurativa","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQN2wzNFdHTDNla2x0M19VRTh3U3BPdzBjZGZIcU1XeWxlbnBMRzd4Q1N3U2dzcmNjS0tJMlFOa1N1YkxEWElaZWw4aFNLS2Y3MTY1LWdmUVdSaXdKdmc4cDY3WHNJSzFiSzNHbUx3SkpxUWtyVWYtMDQyUDJqSHVlYjcxb1VrcmVVc3FPXzRrZDc3Rmt0Wkp6cmFsSkwwMGl5U3UzS1k3d1hwZnBU?oc=5","date":"2025-06-27","type":"pipeline","source":"statnews.com","summary":"Proposed cuts could have ‘catastrophic effect,’ 110 biomedical, health sciences industry leaders tell Congress - statnews.com","headline":"Proposed cuts could have ‘catastrophic effect,’ 110 biomedical, health sciences industry leaders tell Congress","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQOGtZbG00N1Y4cGVCcXR6NEpFY0VqU0h4ZGpRQ3FadGpXOFdSeXZ1UzYtNXF2ZlpGd1BMaGRWNFpoM0lxRWtlS0xEb2szcDdEa25FNTVNNDlNRTlzREJJcjlPeEI3dGl2TXY1THBpV3I5SlFWeU9vdGVQYjM0T3lmMXNMcE45QXlDSXc2WjBUeTJUbjhmdnRJS1huVTBrdlBpX2hFbHVoQ2szX0RpNklvazJ6SQ?oc=5","date":"2024-01-19","type":"pipeline","source":"Fierce Biotech","summary":"Chutes & Ladders—Hardy replaces BioMarin’s commercial chief in first big move as CEO - Fierce Biotech","headline":"Chutes & Ladders—Hardy replaces BioMarin’s commercial chief in first big move as CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxOZWZSdnp6ejhYNFZDMVhkbXBZNTB0OUJXbzR1MllmcTVtTXhrZ0RJeDYwTGpnZU5aNkRIQ0tOTEZYTk9BbmpDLWNuY05xWFRwNHlPU0d3VGRrM3NTQVhmb2ZUWnlnT3hHU3BVRGlEbzdfSzBGTUE3NlZuQWZBdWpIWko4ZXF5STlZUk0tZXRldEs4b01BWVBfczBxbGxXdW9OblV6dGNaakFjbmE4aWRvR2VnNGw2ZGFCRmVJOU1SZ1JWQWYxOHVIaWpGUUpEd3Y4WUE?oc=5","date":"2024-01-18","type":"pipeline","source":"prnewswire.com","summary":"Immunitas Therapeutics Appoints Annalisa D'Andrea, Ph.D., as Chief Scientific Officer - prnewswire.com","headline":"Immunitas Therapeutics Appoints Annalisa D'Andrea, Ph.D., as Chief Scientific Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQQ2N5dDJqU1FDaWVDdFBXdlhFSEh0Z3YtamJDclJmZUlpemM0TlUwUjhGeHJtcjBmWnRKRkl4QndWSWhQOV9ZSG5rMGNaUTg5d21BQ2d6TGpjd3pGU3JKOGhRNVVWclpGZzZNTGxrUmNieDhVeXF6eEJlQXNnMTlEdnhwMmVGWUt6bm9odzJ2MGVyM2gzMzRiOGx3?oc=5","date":"2023-12-13","type":"pipeline","source":"The Pharma Letter","summary":"Electra Therapeutics appoints new chief executive - The Pharma Letter","headline":"Electra Therapeutics appoints new chief executive","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxPdnlGMV9tLTlOYUg3Q0ZzQWd2WXpWUjExcDVJLVN0Yi03akxSTlYyVGFielFJdUlGZ1JPdUtfY3VwNnVrWGFCWHdWcEtHOEs0RU81cmsweUx6c2R4NnB5OFNIbmtpNlVxc0RMbjJMc1lJUmFTTVBOMDRpNF9oSF9kUzRDcVlDdkxNVi1LMmEwMzVXaEF6NWF2Z21PLVJPc0Z5UWhnZEdRV2pVblE1WUdpVWVrUzN2YjVINnpVTzRNTzYzYlFaZnNqUXAtUkVHNGlXQnNvcw?oc=5","date":"2023-01-04","type":"trial","source":"prnewswire.com","summary":"Immunitas Therapeutics Announces First Patient Dosed in Phase 1/2a Study of IMT-009 - prnewswire.com","headline":"Immunitas Therapeutics Announces First Patient Dosed in Phase 1/2a Study of IMT-009","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPMXRmalZDNGR3bk1xRDdkd1pvcUdpWm4wOEllRlJGMVF1eGlnd0hhTVdxN01Ud014SXNodVZLT0NtOTJRUEY3RXFtZHpFZ1Ryd2U3MDRsbXRZTk9RNDdvOGxoblNxdlRnSy00Z0o5SUo3S2tTM3pfWGYtdEdtMXNoYzVfa3VsSUk0VE44WXY2aGNGTXdVd0prWjJMZ05KWGFGc0V2OHU5Qjhycy1IWURKb3lWbw?oc=5","date":"2022-07-15","type":"regulatory","source":"Fierce Biotech","summary":"Chutes & Ladders—Agios makes CEO change less than 6 months after latest FDA approval - Fierce Biotech","headline":"Chutes & Ladders—Agios makes CEO change less than 6 months after latest FDA approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOVER6S2ZxbDBEdzYwSzBMSGEwLUQyTk1zUlFqZGdSYVpZWGxaM0FlZHEyVFpaOWJ6RXh1UzhWMGUzN3llbGc1Ny10eGJPRjhCQlE3aVVuVVE2TGEyVFg0V19ickY1XzRRQWtnaFhnaTU3cENqeEg3eVMxZXRxTS1tR2lLNzQ3c2tybGMtZzVISTR2NXh0MFZiSTFveHhwanJHVGRvNFJpYTA?oc=5","date":"2021-11-25","type":"pipeline","source":"The Business Journals","summary":"Immunitas Therapeutics CEO Amanda Wagner discusses immuno-oncology, Lady Gaga - The Business Journals","headline":"Immunitas Therapeutics CEO Amanda Wagner discusses immuno-oncology, Lady Gaga","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2cxemx5VmFQRVlLYlBsSXlYOVhkeHZWdGJNZ2lhQ2NxX3lYUmprUV9nWUpNVm81TzJyZl9GeGRDZ3FCdUx5UnhuTV9VeGR2Zm5xVU1kWHY5QWhiVWRGZTV6eEFYYzlya3BMbW55Z0dMeFhvOGVFV0JKVk5oQ1JEaG44eFdFRUJuZEpuNjVxLUZLbS1ibjlLVHdmSkFYbmd6anlNWFhLaXE?oc=5","date":"2021-11-16","type":"pipeline","source":"prnewswire.com","summary":"Immunitas Therapeutics Names Amanda Wagner as CEO - prnewswire.com","headline":"Immunitas Therapeutics Names Amanda Wagner as CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQbTlRdzRoalhYSU9SVjFuQWx6TmR5bFc5TmExOG0xZjZuM29zbmFtQXJSdmtMLVRaem9KcUFVRDduU05EcEs4NlAxSVJZZ04tVVBRTDVPNURqemFyZFFld1pFQnpLMnZRRXlUbWczRkU1S0tOemJ4N0pwbjFYbzAzM0QyX3hqYzdLSkkxa0VTXzBuX1NiZURTNnhIY0ctMThHSGdzbmpfRFBHdnRETDQyMW83aGMxa3BRSW1tUzZ6OA?oc=5","date":"2021-08-18","type":"pipeline","source":"Fierce Biotech","summary":"Bayer, Novartis-backed Immunitas secures $58M series B to push new checkpoint inhibitors past blockade - Fierce Biotech","headline":"Bayer, Novartis-backed Immunitas secures $58M series B to push new checkpoint inhibitors past blockade","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2021-08-18","type":"pipeline","source":"prnewswire.com","summary":"Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic and Expand Single Cell Analysis Drug Development Platform for Immuno-Oncology and Other Diseases - p","headline":"Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic and Expand Single Ce","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}